#United States #New York #Citius Pharmaceuticals #LYMPHIR #Citius Oncology

Citius Pharmaceuticals Engages Investors in October 2026

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR), a prominent biopharmaceutical enterprise focused on pioneering critical care solutions, has announced its participation in two investor conferences planned for October 2026 in New York City. With the renowned Chairman and CEO Leonard Mazur at the helm, the company aims to connect with investors and provide key insights into its business trajectory and recent advancements.

Key Events Scheduled

Citius Pharmaceuticals will host its presentations at the 2026 Maxim Growth Summit and the ThinkEquity Conference. The details of these events are as follows:

Maxim Growth Summit

• - Dates: October 12-14, 2026
• - Location: Hard Rock Hotel, New York, NY

ThinkEquity Conference

• - Date: October 15, 2026
• - Location: Mandarin Oriental, New York, NY
• - Presentation Time: 3:00 PM - 3:30 PM ET

Investors who wish to schedule one-on-one meetings with Citius management can do so by reaching out through their conference representative or the company's investor relations team.

Overview of Citius Pharmaceuticals

Citius Pharmaceuticals is dedicated to the development and commercialization of groundbreaking critical care products. The company holds approximately 71% of Citius Oncology, Inc. (Nasdaq CTOR), a subsidiary focusing on oncology solutions. In December 2025, Citius Oncology initiated the launch of LYMPHIR® (denileukin diftitox-cxdl), a targeted immunotherapy designed for adults grappling with relapsed or refractory Stage I-III Cutaneous T-Cell Lymphoma (CTCL) following previous systemic therapy.

The market potential for LYMPHIR is substantial, estimated at over $400 million, affirming its urgency amidst a landscape lacking adequate treatments. The company has established robust intellectual property protections that bolster its competitive advantage, including pharmaceuticals under the orphan drug designation and a comprehensive strategy integrating immuno-oncology approaches.

Advancements and Pipeline

Citius Pharma's commitment to innovation is further exemplified by its late-stage product candidates, including Mino-Lok®, a catheter lock solution aimed at salvaging catheters in patients suffering from catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation targeting hemorrhoid relief. Both products completed pivotal clinical trials in 2023, with Mino-Lok achieving critical benchmarks in its Phase 3 trial, confirming its efficacy and safety.

Engagement with the FDA is ongoing as Citius Pharma seeks to delineate the next steps for both Mino-Lok and Halo-Lido, positioning the company for future growth and enhanced market presence. The upcoming conference presentations are crucial opportunities for Citius Pharmaceuticals to not only showcase its accomplishments but to also discuss its strategic roadmap with potential investors.

Concluding Thoughts

As Citius Pharmaceuticals prepares for these key industry events, it remains committed to driving advancements in the therapeutic landscape while fostering strong relationships with investors. The company's focus on critical care product development continues to pave the way for impactful healthcare solutions, addressing underserved medical needs and reinforcing its position as a leader in the biopharmaceutical sector.

For further details, including live updates and additional insights on the upcoming conferences, please visit Citius Pharmaceuticals and Citius Oncology.

Investor Contact

Ilanit Allen
Email: [email protected]
Phone: 908-967-6677 x113

Media Contact

STiR Communications
Greg Salsburg
Email: [email protected]

Stay tuned as Citius Pharmaceuticals navigates these significant investor engagements while continuing to innovate in the field of biopharmaceuticals.